NCT02124083View on ClinicalTrials.gov

Phase 1/2 Study of Vorinostat Therapy in Niemann-Pick Disease, Type C1

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

April 25, 2014

Primary Completion Date

December 13, 2016

Study Completion Date

December 13, 2016

Conditions
Neimann-Pick Disease
Interventions
DRUG

Vorinostat

Histone deactylase inhibitor

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
collaborator

Washington University School of Medicine

OTHER

collaborator

Weill Medical College of Cornell University

OTHER

lead

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

NCT02124083 - Phase 1/2 Study of Vorinostat Therapy in Niemann-Pick Disease, Type C1 | Biotech Hunter | Biotech Hunter